Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

Comparative Protein Modelling by Satisfaction of Spatial Restraints

Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977 · see citing works

UniProt: the Universal Protein knowledgebase

Apweiler, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkh131 · Cited by 7,535 · see citing works

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works

UniProt: the universal protein knowledgebase

The UniProt Consortium (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1099 · Cited by 4,436 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,124 · see citing works

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works

Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer

Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862 · see citing works

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Beà, S., Valdés‐Mas, R., Villamor, N., Gutiérrez‐Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 813 · see citing works

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 796 · see citing works

Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

Rajala, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H. A., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T. L., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 775 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locations

Anderson, J. R., Armitage, J. O., & Weisenburger, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008265532487 · Cited by 686 · see citing works

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma

Sakata‐Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y., Muto, H., Tsuyama, N., Sato‐Otsubo, A., Okuno, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2872 · Cited by 649 · see citing works

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 647 · see citing works

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563 · see citing works

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

Milner, J. D., Vogel, T. P., Forbes, L. R., Ma, C. A., Stray‐Pedersen, A., Niemela, J. E., Lyons, J. J., Engelhardt, K. R., Zhang, Y., Topcagic, N., et al. (2014) · Blood · doi:10.1182/blood-2014-09-602763 · Cited by 560 · see citing works

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Beà, S., Valdés‐Mas, R., Villamor, N., Gutiérrez‐Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546 · see citing works

Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression

Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K., Firpo, M., Mulvihill, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 531 · see citing works

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaPreprint

Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 524 · see citing works

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Kwong, Y., Chan, T. S. Y., Tan, D. C. L., Kim, S. J., Poon, L. M., Mow, B. M. F., Khong, P., Loong, F., Au-Yeung, R. K. H., Iqbal, J., et al. (2017) · Blood · doi:10.1182/blood-2016-12-756841 · Cited by 497 · see citing works

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

Crescenzo, R., Abate, F., Lasorsa, E., Tabbò, F., Gaudiano, M., Chiesa, N., Giacomo, F. D., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.006 · Cited by 445 · see citing works

Genomic landscape of cutaneous T cell lymphoma

Choi, J., Goh, G., Walradt, T. J., Hong, B. S., Bunick, C. G., Chen, K., Bjornson, R. D., Maman, Y., Wang, T. L., Tordoff, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3356 · Cited by 429 · see citing works

STAT3 Is Required for the gp130-mediated Full Activation of the c-myc Gene

Kiuchi, N., Nakajima, K., Ichiba, M., Fukada, T., Narimatsu, M., Mizuno, K., Hibi, M., & Hirano, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.1.63 · Cited by 396 · see citing works

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Küçük, C., Jiang, B., Hu, X., Zhang, W., Chan, J. K. C., Xiao, W., Lack, N. A., Alkan, C., Williams, J. C., Avery, K. N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7025 · Cited by 394 · see citing works

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Xu-Monette, Z. Y., Wu, L., Visco, C., Tai, Y. C., Tzankov, A., Liu, W., Montes‐Moreno, S., Dybkær, K., Chiu, A., Orazi, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433334 · Cited by 390 · see citing works

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

Jiang, L., Gu, Z., Yan, Z., Zhao, X., Xie, Y., Zhang, Z., Pan, C., Hu, Y., Cai, C., Dong, Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3358 · Cited by 368 · see citing works

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Walters, D. K., Mercher, T., Gu, T., O'Hare, T., Tyner, J., Loriaux, M., Goss, V., Lee, K. A., Eide, C., Wong, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 347 · see citing works

Systematic Functional Annotation of Somatic Mutations in Cancer

Ng, P. K., Li, J., Jeong, K. J., Shao, S. H., Chen, H., Tsang, Y. H., Sengupta, S., Wang, Z., Bhavana, V. H., Tran, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.021 · Cited by 328 · see citing works

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

Weniger, M. A., Melzner, I., Menz, C. K., Wegener, S., Bucur, A. J., Dorsch, K., Mattfeldt, T., Barth, T. F. E., & Mӧller, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209151 · Cited by 324 · see citing works

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G. A., Yelensky, R., Hricik, T., McKenney, A. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407792111 · Cited by 301 · see citing works

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

Koo, G. C., Tan, S., Tang, T. P. L., Poon, S. L., Allen, G. E., Tan, L. H. C., Chong, S. C., Ong, W. S., Tay, K. K. W., Tao, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0028 · Cited by 275 · see citing works

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 262 · see citing works

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

Pilati, C., Amessou, M., Bihl, M., Balabaud, C. P., Nhieu, J. T. V., Paradis, V., Nault, J., Izard, T., Bioulac‐Sage, P., Couchy, G., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110283 · Cited by 242 · see citing works

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

Vasmatzis, G., Johnson, S. H., Knudson, R. A., Ketterling, R. P., Braggio, E., Fonseca, R., Viswanatha, D. S., Law, M. E., Kip, N. S., Özsan, N., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419937 · Cited by 234 · see citing works

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

Melzner, I., Bucur, A. J., Brüderlein, S., Dorsch, K., Hasel, C., Barth, T. F. E., Leithäuser, F., & Möller, P. (2004) · Blood · doi:10.1182/blood-2004-09-3701 · Cited by 215 · see citing works

Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome

Kiel, M. J., Sahasrabuddhe, A. A., Rolland, D. C. M., Velusamy, T., Chung, F., Schaller, M. A., Bailey, N. G., Betz, B. L., Miranda, R. N., Porcu, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9470 · Cited by 209 · see citing works

STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC

Bu, L., Yu, G., Wu, L., Mao, L., Deng, W., Liu, J., Kulkarni, A. B., Zhang, W. F., Zhang, L., & Sun, Z. (2017) · Journal of Dental Research · doi:10.1177/0022034517712435 · Cited by 200 · see citing works

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

Atsaves, V., Tsesmetzis, N., Chioureas, D., Kis, L. L., Leventaki, V., Drakos, E., Panaretakis, T., Grandér, D., Medeiros, L. J., Young, K. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.103 · Cited by 184 · see citing works

Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1α RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells

Niu, G., Briggs, J., Deng, J., Ma, Y., Lee, H., Kortylewski, M., Kujawski, M., Kay, H. D., Cress, W. D., Jove, R., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2177 · Cited by 177 · see citing works

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

Lee, S., Park, H. Y., Kang, S. Y., Kim, S. J., Hwang, J., Lee, S., Kwak, S. H., Park, K. S., Yoo, H. Y., Kim, W. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3776 · Cited by 174 · see citing works

On Human Disease-Causing Amino Acid Variants: Statistical Study of Sequence and Structural Patterns

Petukh, M. G., Kucukkal, T. G., & Alexov, E. G. (2015) · Human Mutation · doi:10.1002/humu.22770 · Cited by 166 · see citing works

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

Bouchekioua, A., Scourzic, L., Wever, O. D., Zhang, Y., Cervera, P., Aline-Fardin, A., Mercher, T., Gaulard, P., Nyga, R., Jeziorowska, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.157 · Cited by 161 · see citing works

Yin–Yang of costimulation: crucial controls of immune tolerance and function

Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157 · see citing works

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma

Nairismägi, M., Tan, J. Y., Lim, J. Q., Nagarajan, S., Ng, C. C. Y., Rajasegaran, V., Huang, D., Lim, W. K., Laurensia, Y., Wijaya, G.-C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.13 · Cited by 151 · see citing works

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

Ooi, W. F., Xing, M., Xu, C., Yao, X., Ramlee, M. K., Lim, M. C., Cao, F., Lim, K. J., Babu, D., Poon, L.-F., et al. (2016) · Nature Communications · doi:10.1038/ncomms12983 · Cited by 146 · see citing works

Simultaneous inhibition of PI3Kδ and PI3Kα induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-κB and AKT

Paul, J., Soujon, M., Wengner, A. M., Zitzmann-Kolbe, S., Sturz, A., Haike, K., Keng Magdalene, K. H., Tan, S. H., Lange, M., Tan, S. Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.003 · Cited by 146 · see citing works

Activating mutations in human acute megakaryoblastic leukemia

Malinge, S., Ragu, C., Della-Valle, V., Pisani, D. F., Constantinescu, S. N., Pérez, C., Villeval, J., Reinhardt, D., Landman‐Parker, J., Michaux, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136366 · Cited by 145 · see citing works

Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification

Ascani, S., Zinzani, P. L., Gherlinzoni, F., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008200307625 · Cited by 136 · see citing works

Epstein-Barr Virus LMP1 Activates EGFR, STAT3, and ERK through Effects on PKCδ

Kung, C.-P., Meckes, D., & Raab-Traub, N. (2011) · Journal of Virology · doi:10.1128/jvi.01703-10 · Cited by 136 · see citing works

Frequent BCOR aberrations in extranodal NK/T ‐Cell lymphoma, nasal type

Dobashi, A., Tsuyama, N., Asaka, R., Togashi, Y., Ueda, K., Sakata, S., Baba, S., Sakamoto, K., Hatake, K., & Takeuchi, K. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22348 · Cited by 131 · see citing works

STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma

Coppo, P., Gouilleux‐Gruart, V., Huang, Y., Bouhlal, H., Bouamar, H., Bouchet, S., Perrot, C., Vieillard, V., Dartigues, P., Gaulard, P., et al. (2009) · Leukemia · doi:10.1038/leu.2009.91 · Cited by 113 · see citing works

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

Jo, J., Kim, M., Choi, Y., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2818-4 · Cited by 110 · see citing works

Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas

Nicolae, A., Xi, L., Pham, T. H., et al. (2016) · Leukemia · doi:10.1038/leu.2016.178 · Cited by 97 · see citing works

Mutations in the signal transducer and activator of transcription family of genes in cancer

Shahmarvand, N., Nagy, A., Shahryari, J., et al. (2018) · Cancer Science · doi:10.1111/cas.13525 · Cited by 85 · see citing works

Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis

Kim, W. Y., Jung, H. Y., Nam, S. J., Kim, T. M., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2011-0 · Cited by 82 · see citing works

Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses

Wang, W., Yen, M., Liu, K., Hsu, P., Sytwu, H., Chen, P., Sudhir, P., Chen, C., Chen, C., Hk, S., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.07.013 · Cited by 80 · see citing works

Targeted Mutational Profiling of Peripheral T-Cell Lymphoma Not Otherwise Specified Highlights New Mechanisms in a Heterogeneous Pathogenesis

Schatz, J., Horwitz, S., Teruya-Feldstein, J., Lunning, M., Viale, A., Huberman, K., Socci, N., Lailler, N., Heguy, A., Dolgalev, I., et al. (2014) · Leukemia · doi:10.1038/leu.2014.261 · Cited by 75 · see citing works

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

Andersson, E. I., Kuusanmäki, H. A., Bortoluzzi, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.263 · Cited by 74 · see citing works

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

Pérez, C., González‐Rincón, J., Onaindía, A., Almaráz, C., García‐Díaz, N., Pisonero, H., Curiel‐Olmo, S., Gómez, S., Cereceda, L., Madureira, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.132837 · Cited by 73 · see citing works

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Bang, Y., Muro, K., Fuchs, C. S., Golan, T., Geva, R., Hara, H., Jalal, S. I., Borg, C., Doi, T., Wainberg, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4012 · Cited by 73 · see citing works

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

Couronné, L., Scourzic, L., Pilati, C., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.085068 · Cited by 56 · see citing works

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

Sim, S. H., Kim, S., Kim, T. M., Jeon, Y. K., Nam, S. J., Ahn, Y., Keam, B., Park, H. H., Kim, D., Kim, C. W., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.004 · Cited by 55 · see citing works

Oncogenic role of miR ‐155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

Merkel, O., Hamacher, F., Griessl, R., Grabner, L., Schiefer, A., Prutsch, N., Baer, C. R., Egger, G., Schlederer, M., Krenn, P. W., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4539 · Cited by 54 · see citing works

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma

Han, L., Liu, F., Li, R., Li, Z., Chen, X., ZHOU, Z., Zhang, X., Hu, T., Zhang, Y., Young, K. H., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2356 · Cited by 52 · see citing works

p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma

Rassidakis, G. Z., Thomaides, A. X., Wang, S., Jiang, Y., Fourtouna, A., Lai, R., & Medeiros, L. J. (2005) · Leukemia · doi:10.1038/sj.leu.2403840 · Cited by 52 · see citing works

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas

Chong, L. C., Twa, D. D. W., Mottok, A., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683003 · Cited by 52 · see citing works

STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds

Nabhani, S., Schipp, C., Miskin, H., Levin, C., Postovsky, S., Dujovny, T., Koren, A., Harlev, D., Bis, A.-M., Auer, F., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.05.021 · Cited by 51 · see citing works

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Schif, B., Lennerz, J. K., Kohler, C. W., Bentink, S., Kreuz, M., Melzner, I., Ritz, O., Trümper, L. H. P., Loeffler, M., Spang, R., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.774 · Cited by 49 · see citing works

GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells

Fazil, M. H. U. T., Ong, S. T., Chalasani, M. L. S., et al. (2016) · Scientific Reports · doi:10.1038/srep37721 · Cited by 47 · see citing works

Phenotypic analysis of peripheral T cell lymphoma among the Japanese

Nakamura, S., Koshikawa, T., Koike, K., et al. (1993) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1993.tb01151.x · Cited by 44 · see citing works

Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera

Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41 · see citing works

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2

Ren, Z., Aerts, J. L., Vandenplas, H., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.430 · Cited by 39 · see citing works

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms

Gäbler, K., Behrmann, I., & Haan, C. (2013) · JAK-STAT · doi:10.4161/jkst.25025 · Cited by 38 · see citing works

Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report

Lai, J., Xu, P., Jiang, X.-L., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3501-4 · Cited by 27 · see citing works

Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK/T-Cell Lymphoma, Nasal Type

Jo, J., Choi, Y., Cha, H. J., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1461.1461 · Cited by 26 · see citing works

Mutations in the JAK / STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T‐cell lymphoma

Manso, R., Sánchez‐Beato, M., González‐Rincón, J., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14984 · Cited by 24 · see citing works

Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma

Ehrentraut, S., Schneider, B., Nagel, S., Pommerenke, C., Quentmeier, H., Geffers, R., Feist, M., Kaufmann, M., Meyer, C., Kadin, M. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9077 · Cited by 22 · see citing works

STAT 3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice

Dutta, A., Yan, D., Hutchison, R. E., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14487 · Cited by 22 · see citing works

Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors

Martinez, G. S., Ross, J. A., & Kirken, R. A. (2016) · Clinical Cancer Drugs · doi:10.2174/2212697x03666160610085943 · Cited by 20 · see citing works

An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing

Loong, S. L. E., Hwang, J. S. G., Lim, S.-T., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802043879 · Cited by 11 · see citing works

[Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line].

Barth, T. F. E., Melzner, I., Wegener, S., Bucur, A. J., Brüderlein, S., Dorsch, K., Hasel, C., Leithäuser, F., & Møller, P. (2005) · PubMed · Cited by 7 · see citing works

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233 · see citing works

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells

Li, Q., Zhang, L., You, W., Xu, J., Dai, J., Hua, D., Zhang, R., Yao, F., Zhou, S., Huang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35469-x · Cited by 128 · see citing works

WSV181 inhibits JAK/STAT signaling and promotes viral replication in Drosophila

Wang, W., Pan, C., Huang, Z., Yuan, H., & Chen, J. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.11.003 · Cited by 14 · see citing works

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

Xie, H., & Li, Y. (2021) · Chinese Journal of Dermatology · doi:10.35541/cjd.20200715

Roles of JAK/STAT Signal Pathway in Lymphoma

Qia, Z. (2014) · Zhongguo shengwu huaxue yu fenzi shengwu xuebao

JAK/STAT Pathway in Drosophila Immunity

Myllymäki, H., & Rämet, M. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12170 · Cited by 205 · see citing works

Regulation of JAK–STAT signalling in the immune system

Shuai, K., & Liu, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1226 · Cited by 1,379 · see citing works